hotspot -WSS

hotspot

author：focus 2025-09-30 23:19:37 - browse：1

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Scientists boost immune system in aging mice by making it youthful

Wikipedia

WSS

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Severe heat forecast: Where scorching temperatures will persist over the next week

There's no autism epidemic. It's an autism diagnosis epidemic

PrEP can help anyone prevent HIV. Why do so few people take it?

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

PrEP can help anyone prevent HIV. Why do so few people take it?

Peter Hotez and the public health issue of online harassment

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Sports medicine is finally prioritizing gender equality

Abortion pill case raises question: who can sue the FDA?

What does generative AI mean for health care? We asked experts

My chronic pain journey would have been easier knowing 5 things % STAT

focus

Malaysia cuts short music fest after British band slams anti

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Abortion pill Supreme Court ruling could impact entire drug industry

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

leisure time

entertainment

Wikipedia

explore